Other — Double advantages of 2D coordination polymer of coumarinyl-pyridyl Schiff base decorated Zn(II): The fabrication of Schottky device and Anti-carcinogenic activity

3 measurement groups · 16 results

Reported values remain attached to the sample, method, conditions, extraction quality and source location that produced them.

as-synthesised powdered Zn(II)-CP · Powder

HeLa cells treated with Zn(II)-CP at 10, 20 and 40 microg/mL for 24 h.

Temperature: 310
Atmosphere: cell-culture conditions
Context: pristine framework biological application
Measurement source: 9-10 · 3.5 Inhibition in cell cycle progression · Figure 11

Property	Reported value	Normalised value	Uncertainty	Origin and quality	Source
caspase 3 activity increase at 10 microg/mL	1.62-fold	—	—	Text Exact Reported	10 · 3.5 Inhibition in cell cycle progression · Figure 11c
caspase 3 activity increase at 20 microg/mL	1.89-fold	—	—	Text Exact Reported	10 · 3.5 Inhibition in cell cycle progression · Figure 11c
caspase 3 activity increase at 40 microg/mLMarked as a best value within this paper	2.48-fold	—	—	Text Exact Reported	10 · 3.5 Inhibition in cell cycle progression · Figure 11c
G2/M arrested cell population at 10 microg/mL	31.22%	—	—	Text Exact Reported	9 · 3.5 Inhibition in cell cycle progression · Figure 11a,b
G2/M arrested cell population at 20 microg/mL	57.85%	—	—	Text Exact Reported	9 · 3.5 Inhibition in cell cycle progression · Figure 11a,b
G2/M arrested cell population at 40 microg/mLMarked as a best value within this paper	68.39%	—	—	Text Exact Reported	9 · 3.5 Inhibition in cell cycle progression · Figure 11a,b

as-synthesised powdered Zn(II)-CP · Powder

HeLa, MDA-MB-231, HepG2 and NKE cells treated with Zn(II)-CP at 0-100 microg/mL in DMSO for 24 h.

Property	Reported value	Normalised value	Uncertainty	Origin and quality	Source
IC50 against HeLa cellsMarked as a best value within this paper	21.02 +/- 1.57 microg/mL	—	+/- 1.57	Text Exact Reported	7 · 3.3 Biological applications · Figure 9
IC50 against HepG2 cells	42.22 +/- 3.45 microg/mL	—	+/- 3.45	Text Exact Reported	7 · 3.3 Biological applications · Figure 9
IC50 against MDA-MB-231 cells	46.37 +/- 3.06 microg/mL	—	+/- 3.06	Text Exact Reported	8 · 3.3 Biological applications · Figure 9

as-synthesised powdered Zn(II)-CP · Powder

HeLa cells treated with Zn(II)-CP at 10, 20 and 40 microg/mL for 24 h; NAC pretreatment used in ROS assay.

Temperature: 310
Atmosphere: cell-culture conditions
Context: pristine framework biological application
Measurement source: 8-9 · 3.4 Apoptotic cell death and intracellular ROS generation · Figure 10

Property	Reported value	Normalised value	Uncertainty	Origin and quality	Source
apoptotic cell population at 10 microg/mL	24.39%	—	—	Text Exact Reported	8 · 3.4 Apoptotic cell death and intracellular ROS generation · Figure 10b
apoptotic cell population at 20 microg/mL	35.15%	—	—	Text Exact Reported	8 · 3.4 Apoptotic cell death and intracellular ROS generation · Figure 10b
apoptotic cell population at 40 microg/mLMarked as a best value within this paper	69.35%	—	—	Text Exact Reported	8 · 3.4 Apoptotic cell death and intracellular ROS generation · Figure 10b
apoptotic cell population, control	2.24%	—	—	Text Exact Reported	8 · 3.4 Apoptotic cell death and intracellular ROS generation · Figure 10b
ROS fluorescence intensity increase at 10 microg/mL	2.24-fold	—	—	Text Exact Reported	8 · 3.4 Apoptotic cell death and intracellular ROS generation · Figure 10a
ROS fluorescence intensity increase at 20 microg/mL	4.25-fold	—	—	Text Exact Reported	8 · 3.4 Apoptotic cell death and intracellular ROS generation · Figure 10a
ROS fluorescence intensity increase at 40 microg/mLMarked as a best value within this paper	4.92-fold	—	—	Text Exact Reported	8 · 3.4 Apoptotic cell death and intracellular ROS generation · Figure 10a